BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 1529628)

  • 1. [Changes in systemic fibrinolysis and blood coagulation parameters in local thrombolysis with tissue plasminogen activator (rt-PA)].
    Klein P; Roth FJ; Rieger H; Popov-Cenic S
    Vasa; 1992; 21(3):249-52. PubMed ID: 1529628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases].
    Izaguirre Avila R; Ruiz de Chávez Cervantes A; Villavicencio R; Gómez Trigos A; Mar Chavira R; Spíndola Mdel C; Casanova JM
    Arch Inst Cardiol Mex; 1993; 63(3):235-40. PubMed ID: 8347053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
    Stehling F; Weber R; Ozcelik A; Bröcker M; Volbracht L; Diener HC; Busch E
    Neurosci Lett; 2008 Aug; 441(1):39-43. PubMed ID: 18597942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Local low dosage thrombolysis with rt-PA. Systemic effects on the fibrinolytic system--data on the assessment of the value and risk of this method].
    von Bilderling P; Spannagl M; Mietaschk A; Iven M; Schramm W; Hess H
    Vasa Suppl; 1991; 33():132-3. PubMed ID: 1788645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
    Verstraete M; Su CA; Tanswell P; Feuerer W; Collen D
    Thromb Haemost; 1986 Aug; 56(1):1-5. PubMed ID: 3095944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.
    Garcia-Avello A; Garcia-Frade LJ; Gandarias C; Ocaña J; Cancelas JA; Lasso M
    Thromb Res; 1994 Jan; 73(2):109-15. PubMed ID: 8171409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
    Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O
    Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic therapy with recombinant human tissue-type plasminogen activator: a comparison of two doses.
    Risius B; Graor RA; Geisinger MA; Zelch MG; Lucas FV; Young JR
    Radiology; 1987 Aug; 164(2):465-8. PubMed ID: 3110860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
    Kruithof EK; Mestries JC; Gascon MP; Ythier A
    Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemostasis in oral surgery--the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system.
    Sindet-Pedersen S
    Dan Med Bull; 1991 Dec; 38(6):427-43. PubMed ID: 1802633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.